Tiziana Vaisitti

List of Publications by Year
in descending order

99 papers	4,481 citations	159585 30 h-index	106344 65 g-index
101 all docs	101 docs citations	101 times ranked	6343 citing authors

#	Article	IF	Citations
1	Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology. Physiological Reviews, 2008, 88, 841-886.	28.8	727
2	The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development. Journal of Experimental Medicine, 2012, 209, 1537-1551.	8.5	363
3	Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood, 2011, 118, 6904-6908.	1.4	342
4	Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood, 2012, 119, 2854-2862.	1.4	257
5	CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood, 2005, 105, 3042-3050.	1.4	194
6	Alteration of BIRC3 and multiple other NF-Îº B pathway genes in splenic marginal zone lymphoma. Blood, 2011, 118, 4930-4934.	1.4	176
7	Nicotinamide Blocks Proliferation and Induces Apoptosis of Chronic Lymphocytic Leukemia Cells through Activation of the p53/miR-34a/SIRT1 Tumor Suppressor Network. Cancer Research, 2011, 71, 4473-4483.	0.9	153
8	Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood, 2015, 125, 111-123.	1.4	151
9	CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood, 2007, 110, 4012-4021.	1.4	149
10	In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood, 2006, 108, 1135-1144.	1.4	132
11	CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells. Blood, 2006, 107, 2392-2399.	1.4	123
12	CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood, 2011, 118, 6141-6152.	1.4	122
13	CD38/CD19: a lipid raftâ€“dependent signaling complex in human B cells. Blood, 2007, 109, 5390-5398.	1.4	105
14	Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia, 2014, 28, 1060-1070.	7.2	105
15	CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia, 2010, 24, 958-969.	7.2	89
16	HLA and AB0 Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity. Transplantation, 2021, 105, 193-200.	1.0	81
17	Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. International Journal of Molecular Sciences, 2020, 21, 1825.	4.1	80
18	The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia, 2012, 26, 1301-1312.	7.2	78

#	Article	IF	Citations
19	CD38/CD31 Interactions Activate Genetic Pathways Leading to Proliferation and Migration in Chronic Lymphocytic Leukemia Cells. Molecular Medicine, 2010, 16, 87-91.	4.4	68
20	CD38 and CD157 as Receptors of the Immune System: A Bridge Between Innate and Adaptive Immunity. Molecular Medicine, 2006, 12, 334-341.	4.4	66
21	CD38 at the junction between prognostic marker and therapeutic target. Trends in Molecular Medicine, 2008, 14, 210-218.	6.7	62
22	Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22. Leukemia, 2017, 31, 1882-1893.	7.2	52
23	The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies. Frontiers in Oncology, 2018, 8, 550.	2.8	52
24	Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Advances, 2016, 1, 47-61.	5.2	48
25	ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patientâ€“derived xenograft mouse models. Blood, 2021, 137, 3365-3377.	1.4	47
26	SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. Journal of Clinical Investigation, 2015, 126, 181-194.	8.2	44
27	E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia. Leukemia, 2011, 25, 479-488.	7.2	41
28	Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. American Journal of Hematology, 2007, 82, 787-791.	4.1	39
29	The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia, 2015, 29, 356-368.	7.2	33
30	B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation. Blood, 2021, 138, 1053-1066.	1.4	33
31	Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma. Journal of the National Cancer Institute, 2018, 110, 290-303.	6.3	32
32	Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-ÎºB inhibitor. Haematologica, 2017, 102, 1878-1889.	3.5	32
33	Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. Cancer Research, 2018, 78, 3413-3420.	0.9	31
34	CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. Seminars in Cancer Biology, 2010, 20, 416-423.	9.6	28
35	A variant of the <i>LRP4</i> gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. British Journal of Haematology, 2011, 152, 284-294.	2.5	28
36	Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets. Frontiers in Immunology, 2019, 10, 2301.	4.8	28

#	Article	IF	Citations
37	Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richterâ€™s syndrome: therapeutic implications. Leukemia, 2020, 34, 462-477.	7.2	24
38	Synergistic efficacy of the dual PI3K-Î´/Î³ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. Blood, 2021, 137, 3378-3389.	1.4	24
39	NAD⁺â€metabolizing ectoâ€enzymes shape tumorâ€“host interactions: The chronic lymphocytic leukemia model. FEBS Letters, 2011, 585, 1514-1520.	2.8	23
40	CD38 CD49d Are Physically and Functionally Associated in B-Cell Chronic Lymphocytic Leukemia Cells.. Blood, 2009, 114, 357-357.	1.4	23
41	Adult-onset CblC deficiency: a challenging diagnosis involving different adult clinical specialists. Orphanet Journal of Rare Diseases, 2022, 17, 33.	2.7	22
42	NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma. Cancers, 2020, 12, 3855.	3.7	17
43	Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. Cancer Letters, 2013, 328, 27-35.	7.2	16
44	CD38 in Chronic Lymphocytic Leukemia: From Bench to Bedside?. Mini-Reviews in Medicinal Chemistry, 2011, 11, 503-507.	2.4	13
45	Targeting of the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia. Haematologica, 2021, 106, 1343-1353.	3.5	12
46	CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells. Leukemia, 2013, 27, 1177-1181.	7.2	11
47	Clinical exome sequencing is a powerful tool in the diagnostic flow of monogenic kidney diseases: an Italian experience. Journal of Nephrology, 2020, 34, 1767-1781.	2.0	11
48	Subcellular Characterization of Nicotinamide Adenine Dinucleotide Biosynthesis in Metastatic Melanoma by Using Organelle-Specific Biosensors. Antioxidants and Redox Signaling, 2019, 31, 1150-1165.	5.4	9
49	Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?. International Journal of Molecular Sciences, 2018, 19, 1167.	4.1	8
50	Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS). Blood, 2019, 134, 2856-2856.	1.4	8
51	HLA-DRB1 mismatch-based identification of donor-derived cell free DNA (dd-cfDNA) as a marker of rejection in heart transplant recipients: A single-institution pilot study. Journal of Heart and Lung Transplantation, 2021, 40, 794-804.	0.6	7
52	Lift the curtain on long non-coding RNAs in hematological malignancies: Pathogenic elements and potential targets. Cancer Letters, 2022, 536, 215645.	7.2	7
53	Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia. Oncotarget, 2017, 8, 90013-90027.	1.8	5
54	LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells. Hematological Oncology, 2022, 40, 41-48.	1.7	5

#	Article	IF	Citations
55	The frequency of rare and monogenic diseases in pediatric organ transplant recipients in Italy. Orphanet Journal of Rare Diseases, 2021, 16, 374.	2.7	5
56	Chronic Lymphocytic Leukemia. Cancers, 2020, 12, 2504.	3.7	4
57	CD38 Ligation in B-Chronic Lymphocytic Leukemia Cells Induces Sequential Tyrosine Phosphorylation of ZAP70, PLC- Î³2 and ERK1/2 Proteins.. Blood, 2004, 104, 959-959.	1.4	4
58	Multiple Metamorphoses of CD38 from Prognostic Marker to Disease Modifier to Therapeutic Target in Chronic Lymphocytic Leukemia. Current Topics in Medicinal Chemistry, 2013, 13, 2955-2964.	2.1	4
59	Anti-CD37 Alpha-Amanitin Conjugated Antibodies As Therapeutic Weapons for Richter's Syndrome. Blood, 2021, 138, 791-791.	1.4	4
60	Novel Approaches for the Treatment of Patients with Richterâ€™s Syndrome. Current Treatment Options in Oncology, 2022, 23, 526-542.	3.0	4
61	CD79b Expression in Richter's Transformation. Blood, 2019, 134, 4279-4279.	1.4	3
62	Extracellular Nicotinamide Phosphoribosyltransferase (NAMPT) Shapes the CLL Microenvironment Promoting Macrophage M2 Polarization Via a Non-Enzymatic Mechanism. Blood, 2014, 124, 3316-3316.	1.4	3
63	A novel COLEC10 mutation in a child with 3MC syndrome. European Journal of Medical Genetics, 2021, 64, 104374.	1.3	3
64	The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy. Blood, 2021, 138, 3718-3718.	1.4	2
65	A new taxonomy for splenic marginal zone lymphoma. Blood, 2022, 139, 644-645.	1.4	2
66	P0056USE OF CLINICAL EXOME SEQUENCING IN THE DIAGNOSTIC FLOW OF MONOGENIC KIDNEY DISEASES: THE PIEDMONT EXPERIENCE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
67	The Dual PI3K-Î´/Î³ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models. Blood, 2019, 134, 2862-2862.	1.4	1
68	Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis. Blood, 2012, 120, 1770-1770.	1.4	1
69	Alteration of BIRC3 and Multiple Other NF-Î°B Pathway Genes in Splenic Marginal Zone Lymphoma. Blood, 2011, 118, 264-264.	1.4	1
70	Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment. Blood, 2015, 126, 4145-4145.	1.4	1
71	2.35 CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S181.	0.4	0
72	P0051NOVEL AND KNOWN MUTATIONS IDENTIFIED BY CLINICAL EXOME SEQUENCING FOR THE DIAGNOSIS OF POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0

#	Article	IF	Citations
73	MO059COLEC10 AND 3MC SYNDROME: EXPANDING THE GENOTYPIC AND PHENOTYPIC SPECTRUM OF A VERY RARE DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
74	CD38 and ZAP-70 Mark Chronic Lymphocytic Leukemia (CLL) Cells with High Migratory Potential and Regulate Chemotaxis.. Blood, 2007, 110, 4684-4684.	1.4	0
75	Human CD38 Is a Potential Therapeutic Target for Sekected Chronic Lymphocytic Leukemia cases.. Blood, 2008, 112, 2096-2096.	1.4	0
76	CD38 Induces Homing of Chronic Lymphocytic Leukemia Cells to the Lymphoid Organs through a Functional Interplay with CXCR4.. Blood, 2009, 114, 2328-2328.	1.4	0
77	E2A Transcriptionally Regulates CD38 Expression In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 3599-3599.	1.4	0
78	Nicotinamide Promotes Apoptosis In Chronic Lymphocytic Leukemia through Activation of the p53/Mir-34a/SIRT1 Tumor Suppressor Network. Blood, 2010, 116, 4627-4627.	1.4	0
79	CD38 Expression Marks CLL Cells with Invasive Properties. Blood, 2010, 116, 2422-2422.	1.4	0
80	Abstract 389: CD38 is part of a network of molecules regulating chemotaxis and homing of CLL cells. , 2011, , .		0
81	Abstract 1542: CD38 is physically associated with CD49d and enhances CD49d-mediated adhesion of B-Cell chronic lymphocytic leukemia cells. , 2011, , .		0
82	Abstract 2630: Nicotinamide activates the p53/miR-34a/SIRT1 tumor suppressor network leading to apoptosis of chronic lymphocytic leukemia cells. , 2011, , .		0
83	CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells. Blood, 2011, 118, 621-621.	1.4	0
84	CD38 Regulates Homing and Engraftment of CLL Cells,. Blood, 2011, 118, 3873-3873.	1.4	0
85	Abstract 5170: Metabolism and cancer: The CD38-NAMPT connection in chronic lymphocytic leukemia. , 2012, , .		0
86	Abstract 1348: CD38 regulates homing and engraftment in a mouse model of CLL. , 2012, , .		0
87	Circulating CLL Cells Expressing CD49d Display a Phospho-Proteomic Profile Consistent with a Constitutive Receptor Engagement by Blood-Borne Ligands. Blood, 2012, 120, 930-930.	1.4	0
88	The Elastin Microfibril Interfacer-1 (EMILIN-1) Is a Ligand for CD49d in Chronic Lymphocytic Leukemia Cells. Blood, 2012, 120, 1772-1772.	1.4	0
89	Abstract 2302: The extracellular form of NAMPT contributes to creating a proinflammatory environment in chronic lymphocytic leukemia.. , 2013, , .		0
90	Functional Effects Of NOTCH1 Mutations In Chronic Lymphocytic Leukemia Patients. Blood, 2013, 122, 4117-4117.	1.4	0

#	Article	IF	Citations
91	Abstract 3192: Cooperation between adenosinergic and hypoxic signals in shaping chronic lymphocytic leukemia microenvironment. , 2015, , .		0
92	SLAMF1/CD150 Activates Autophagy in Chronic Lymphocytic Leukemia Cells, Modulating Chemotaxis and Responses to Therapy. Blood, 2015, 126, 1728-1728.	1.4	0
93	Mutations in NOTCH1 PEST Domain Orchestrate CCL19-Driven Homing of Chronic Lymphocytic Leukemia (CLL) Cells By Modulating the Tumor Suppressor Gene DUSP22. Blood, 2016, 128, 969-969.	1.4	0
94	Targeting Cellular Metabolism and Survival in Chronic Lymphocytic Leukemia and Richter Syndrome Cells By a Novel NF-Kb Inhibitor. Blood, 2016, 128, 304-304.	1.4	0
95	Targeting the Adenosinergic Axis in the EÎ¼-TCL1 Chronic Lymphocytic Leukemia Mouse Model Offers Novel Therapeutic Opportunities. Blood, 2018, 132, 240-240.	1.4	0
96	HLA and AB0 Polymorphisms Influence SARS-CoV-2 Infection and COVID-19 Severity. SSRN Electronic Journal, 0, , .	0.4	0
97	The frequency of rare and monogenic diseases in pediatric organ transplant recipients in Italy. Orphanet Journal of Rare Diseases, 2021, 16, 374.	2.7	0
98	Evidence of a Synergistic Cross-Talk between the B Cell Receptor (BCR) and Nicotinamide Phosphoribosyl Transferase (NAMPT) in Richter's Syndrome Patient-Derived Xenograft Models: Therapeutic Implications. Blood, 2021, 138, 250-250.	1.4	0
99	Unusual Presentation of Remethylation Disorders: A Case of Later Onset CblE Deficiency. Acta Scientific Paediatrics, 2020, 4, 11-14.	0.1	0